Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro

Y. Nie, D. D. Schoepp, J. E. Klaunig, M. Yard, Debomoy Lahiri, M. J. Kubek

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Excess excitatory amino acid release is involved in pathways associated with seizures and neurodegeneration. Thyrotropin-releasing hormone (TRH; protirelin), a brain-derived tripeptide, has shown efficacy in the treatment of such disorders, yet its mechanism of neuroprotection is poorly understood. Using superfused hippocampal slices, we tested the hypothesis that TRH could inhibit evoked glutamate/aspartate release in vitro. Rat hippocampal slices were first equilibrated in oxygenated Krebs buffer (KRB) (120 min) then superfused for 10 min with KRB (control), or KRB containing 0.1, 1, or 10 μM TRH respectively, prior to and during 5 min depolarization with high potassium KRB (50 mM [K +] ± TRH). Fractions (1 min) were collected during the 5 min stimulation and for an additional 10 min thereafter and analyzed for glutamate and aspartate by HPLC. TRH had no effect on baseline glutamate/aspartate release, while all three TRH doses significantly (P < 0.05) inhibited peak 50 mM [K+]-stimulated glutamate/aspartate release, and glutamate remained below control (P < 0.05) at 15 min post stimulation. A 5 min pulse of TRH (10 μM) had no affect on basal glutamate/aspartate release, whereas the TRH pre-pulsed slices failed to release glutamate/aspartate by [K +]-stimulation given 15 min later. These results are the first to show a potent and prolonged inhibitory effect of TRH on evoked glutamate/aspartate release in vitro. These initial studies suggest that exogenous and/or endogenous TRH may function, in part, to modulate excess glutamate release in specific CNS loci. Additional studies are in progress to fully understand the mechanism of this potent effect of TRH and its implication in various CNS disorders.

Original languageEnglish
Pages (from-to)45-54
Number of pages10
JournalBrain Research
Volume1054
Issue number1
DOIs
StatePublished - Aug 23 2005

Fingerprint

Thyrotropin-Releasing Hormone
Aspartic Acid
Glutamic Acid
Buffers
In Vitro Techniques
Excitatory Amino Acids
Potassium
Seizures
High Pressure Liquid Chromatography
Brain

Keywords

  • Brain slice
  • Glutamate
  • Glutamate antagonist
  • Hippocampus
  • Metabotropic receptor
  • Neurodegeneration
  • Neuroprotection
  • Protirelin
  • Thyrotropin-releasing hormone
  • TRH

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro. / Nie, Y.; Schoepp, D. D.; Klaunig, J. E.; Yard, M.; Lahiri, Debomoy; Kubek, M. J.

In: Brain Research, Vol. 1054, No. 1, 23.08.2005, p. 45-54.

Research output: Contribution to journalArticle

Nie, Y. ; Schoepp, D. D. ; Klaunig, J. E. ; Yard, M. ; Lahiri, Debomoy ; Kubek, M. J. / Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro. In: Brain Research. 2005 ; Vol. 1054, No. 1. pp. 45-54.
@article{5e038adba871438e950537a305273643,
title = "Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro",
abstract = "Excess excitatory amino acid release is involved in pathways associated with seizures and neurodegeneration. Thyrotropin-releasing hormone (TRH; protirelin), a brain-derived tripeptide, has shown efficacy in the treatment of such disorders, yet its mechanism of neuroprotection is poorly understood. Using superfused hippocampal slices, we tested the hypothesis that TRH could inhibit evoked glutamate/aspartate release in vitro. Rat hippocampal slices were first equilibrated in oxygenated Krebs buffer (KRB) (120 min) then superfused for 10 min with KRB (control), or KRB containing 0.1, 1, or 10 μM TRH respectively, prior to and during 5 min depolarization with high potassium KRB (50 mM [K +] ± TRH). Fractions (1 min) were collected during the 5 min stimulation and for an additional 10 min thereafter and analyzed for glutamate and aspartate by HPLC. TRH had no effect on baseline glutamate/aspartate release, while all three TRH doses significantly (P < 0.05) inhibited peak 50 mM [K+]-stimulated glutamate/aspartate release, and glutamate remained below control (P < 0.05) at 15 min post stimulation. A 5 min pulse of TRH (10 μM) had no affect on basal glutamate/aspartate release, whereas the TRH pre-pulsed slices failed to release glutamate/aspartate by [K +]-stimulation given 15 min later. These results are the first to show a potent and prolonged inhibitory effect of TRH on evoked glutamate/aspartate release in vitro. These initial studies suggest that exogenous and/or endogenous TRH may function, in part, to modulate excess glutamate release in specific CNS loci. Additional studies are in progress to fully understand the mechanism of this potent effect of TRH and its implication in various CNS disorders.",
keywords = "Brain slice, Glutamate, Glutamate antagonist, Hippocampus, Metabotropic receptor, Neurodegeneration, Neuroprotection, Protirelin, Thyrotropin-releasing hormone, TRH",
author = "Y. Nie and Schoepp, {D. D.} and Klaunig, {J. E.} and M. Yard and Debomoy Lahiri and Kubek, {M. J.}",
year = "2005",
month = "8",
day = "23",
doi = "10.1016/j.brainres.2005.06.077",
language = "English",
volume = "1054",
pages = "45--54",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro

AU - Nie, Y.

AU - Schoepp, D. D.

AU - Klaunig, J. E.

AU - Yard, M.

AU - Lahiri, Debomoy

AU - Kubek, M. J.

PY - 2005/8/23

Y1 - 2005/8/23

N2 - Excess excitatory amino acid release is involved in pathways associated with seizures and neurodegeneration. Thyrotropin-releasing hormone (TRH; protirelin), a brain-derived tripeptide, has shown efficacy in the treatment of such disorders, yet its mechanism of neuroprotection is poorly understood. Using superfused hippocampal slices, we tested the hypothesis that TRH could inhibit evoked glutamate/aspartate release in vitro. Rat hippocampal slices were first equilibrated in oxygenated Krebs buffer (KRB) (120 min) then superfused for 10 min with KRB (control), or KRB containing 0.1, 1, or 10 μM TRH respectively, prior to and during 5 min depolarization with high potassium KRB (50 mM [K +] ± TRH). Fractions (1 min) were collected during the 5 min stimulation and for an additional 10 min thereafter and analyzed for glutamate and aspartate by HPLC. TRH had no effect on baseline glutamate/aspartate release, while all three TRH doses significantly (P < 0.05) inhibited peak 50 mM [K+]-stimulated glutamate/aspartate release, and glutamate remained below control (P < 0.05) at 15 min post stimulation. A 5 min pulse of TRH (10 μM) had no affect on basal glutamate/aspartate release, whereas the TRH pre-pulsed slices failed to release glutamate/aspartate by [K +]-stimulation given 15 min later. These results are the first to show a potent and prolonged inhibitory effect of TRH on evoked glutamate/aspartate release in vitro. These initial studies suggest that exogenous and/or endogenous TRH may function, in part, to modulate excess glutamate release in specific CNS loci. Additional studies are in progress to fully understand the mechanism of this potent effect of TRH and its implication in various CNS disorders.

AB - Excess excitatory amino acid release is involved in pathways associated with seizures and neurodegeneration. Thyrotropin-releasing hormone (TRH; protirelin), a brain-derived tripeptide, has shown efficacy in the treatment of such disorders, yet its mechanism of neuroprotection is poorly understood. Using superfused hippocampal slices, we tested the hypothesis that TRH could inhibit evoked glutamate/aspartate release in vitro. Rat hippocampal slices were first equilibrated in oxygenated Krebs buffer (KRB) (120 min) then superfused for 10 min with KRB (control), or KRB containing 0.1, 1, or 10 μM TRH respectively, prior to and during 5 min depolarization with high potassium KRB (50 mM [K +] ± TRH). Fractions (1 min) were collected during the 5 min stimulation and for an additional 10 min thereafter and analyzed for glutamate and aspartate by HPLC. TRH had no effect on baseline glutamate/aspartate release, while all three TRH doses significantly (P < 0.05) inhibited peak 50 mM [K+]-stimulated glutamate/aspartate release, and glutamate remained below control (P < 0.05) at 15 min post stimulation. A 5 min pulse of TRH (10 μM) had no affect on basal glutamate/aspartate release, whereas the TRH pre-pulsed slices failed to release glutamate/aspartate by [K +]-stimulation given 15 min later. These results are the first to show a potent and prolonged inhibitory effect of TRH on evoked glutamate/aspartate release in vitro. These initial studies suggest that exogenous and/or endogenous TRH may function, in part, to modulate excess glutamate release in specific CNS loci. Additional studies are in progress to fully understand the mechanism of this potent effect of TRH and its implication in various CNS disorders.

KW - Brain slice

KW - Glutamate

KW - Glutamate antagonist

KW - Hippocampus

KW - Metabotropic receptor

KW - Neurodegeneration

KW - Neuroprotection

KW - Protirelin

KW - Thyrotropin-releasing hormone

KW - TRH

UR - http://www.scopus.com/inward/record.url?scp=23944489345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944489345&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2005.06.077

DO - 10.1016/j.brainres.2005.06.077

M3 - Article

C2 - 16055093

AN - SCOPUS:23944489345

VL - 1054

SP - 45

EP - 54

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -